Literature DB >> 2304147

Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice.

J J Treanor1, E L Tierney, S L Zebedee, R A Lamb, B R Murphy.   

Abstract

The M2 protein of influenza A virus is expressed on the surfaces of infected cells, and a monoclonal antibody to this protein inhibits plaque enlargement of sensitive influenza A viruses without reducing plaque titer (S.L. Zebedee and R.A. Lamb, J. Virol. 62:2762-2772, 1988). In the current study, passively transferred monoclonal antibody to M2 reduced the level of replication of influenza A virus but not of influenza B virus in the lungs of mice. These experiments demonstrated that antibody to a protein conserved among influenza A virus subtypes inhibits virus growth in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2304147      PMCID: PMC249260     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  19 in total

1.  Growth restriction of influenza A virus by M2 protein antibody is genetically linked to the M1 protein.

Authors:  S L Zebedee; R A Lamb
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

2.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.

Authors:  R A Lamb; S L Zebedee; C D Richardson
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

3.  Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis.

Authors:  A L Schmaljohn; E D Johnson; J M Dalrymple; G A Cole
Journal:  Nature       Date:  1982-05-06       Impact factor: 49.962

4.  On the origin of the human influenza virus subtypes H2N2 and H3N2.

Authors:  C Scholtissek; W Rohde; V Von Hoyningen; R Rott
Journal:  Virology       Date:  1978-06-01       Impact factor: 3.616

5.  Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults.

Authors:  D D Richman; B R Murphy; R M Chanock; J M Gwaltney; R G Douglas; R F Betts; N R Blacklow; F B Rose; T A Parrino; M M Levine; E S Caplan
Journal:  J Infect Dis       Date:  1976-12       Impact factor: 5.226

6.  Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo.

Authors:  L Lefrancois
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

7.  Influenzavirus infections in Seattle families, 1975-1979. II. Pattern of infection in invaded households and relation of age and prior antibody to occurrence of infection and related illness.

Authors:  J P Fox; M K Cooney; C E Hall; H M Foy
Journal:  Am J Epidemiol       Date:  1982-08       Impact factor: 4.897

8.  Reduction in plaque size and reduction in plaque number as differing indices of influenza virus-antibody reactions.

Authors:  R I Jahiel; E D Kilbourne
Journal:  J Bacteriol       Date:  1966-11       Impact factor: 3.490

9.  Protection against 17D yellow fever encephalitis in mice by passive transfer of monoclonal antibodies to the nonstructural glycoprotein gp48 and by active immunization with gp48.

Authors:  J J Schlesinger; M W Brandriss; E E Walsh
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

10.  Serum antibody prevents lethal murine influenza pneumonitis but not tracheitis.

Authors:  R Ramphal; R C Cogliano; J W Shands; P A Small
Journal:  Infect Immun       Date:  1979-09       Impact factor: 3.441

View more
  85 in total

1.  Expression of the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells.

Authors:  P G Hughey; R W Compans; S L Zebedee; R A Lamb
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

2.  Epitope specificity of anti-HA2 antibodies induced in humans during influenza infection.

Authors:  Zuzana Staneková; Vojtech Mucha; Tatiana Sládková; Hana Blaškovičová; František Kostolanský; Eva Varečková
Journal:  Influenza Other Respir Viruses       Date:  2012-01-12       Impact factor: 4.380

Review 3.  Novel vaccines against influenza viruses.

Authors:  S M Kang; J M Song; R W Compans
Journal:  Virus Res       Date:  2011-10-01       Impact factor: 3.303

Review 4.  Influenza A viruses: why focusing on M2e-based universal vaccines.

Authors:  Seyyed Mahmoud Ebrahimi; Majid Tebianian
Journal:  Virus Genes       Date:  2010-11-17       Impact factor: 2.332

5.  Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand.

Authors:  Bao-Zhong Wang; Harvinder S Gill; Sang-Moo Kang; Li Wang; Ying-Chun Wang; Elena V Vassilieva; Richard W Compans
Journal:  Clin Vaccine Immunol       Date:  2012-05-30

Review 6.  Development of universal influenza vaccines based on influenza virus M and NP genes.

Authors:  M Zheng; J Luo; Z Chen
Journal:  Infection       Date:  2013-11-01       Impact factor: 3.553

Review 7.  Heterosubtypic immunity to influenza A virus: where do we stand?

Authors:  Kristie M Grebe; Jonathan W Yewdell; Jack R Bennink
Journal:  Microbes Infect       Date:  2008-07-09       Impact factor: 2.700

Review 8.  Towards a universal influenza vaccine: volunteer virus challenge studies in quarantine to speed the development and subsequent licensing.

Authors:  John S Oxford
Journal:  Br J Clin Pharmacol       Date:  2013-08       Impact factor: 4.335

9.  Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein.

Authors:  Roger R Beerli; Monika Bauer; Nicole Schmitz; Regula B Buser; Myriam Gwerder; Simone Muntwiler; Wolfgang A Renner; Philippe Saudan; Martin F Bachmann
Journal:  Virol J       Date:  2009-12-21       Impact factor: 4.099

10.  Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against H5N1 influenza in mouse and ferret.

Authors:  Srinivas S Rao; Wing-Pui Kong; Chih-Jen Wei; Neal Van Hoeven; J Patrick Gorres; Martha Nason; Hanne Andersen; Terrence M Tumpey; Gary J Nabel
Journal:  PLoS One       Date:  2010-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.